References
1
Wiselogle FW.
Survey of Antimalarial Drugs 1941-45
Edwards
Brothers;
Arn Arbor, Michigan:
1946.
2
Herndon JL.
Ismaiel A.
Ingher SP.
Teitler M.
Glennon RA.
J.
Med. Chem.
1992,
35:
4903
3a
Marsham PR.
Jackman AL.
Hayter AJ.
Daw MR.
Snowden JL.
O’Connor BM.
Bishop JAM.
Calvert AH.
Hughes LR.
J. Med. Chem.
1991,
34:
2209
3b
Meshnick SR.
Thomas A.
Ranz A.
Xu CM.
Pan H.
Mol.
Biochem. Parasitol.
1991,
49:
181
3c
Pendergast W.
Dickerson SH.
Dev IK.
Ferone R.
Duch DS.
Smith GK.
J.
Med. Chem.
1994,
37:
838
4a Sumitomo CC. inventors; Fr. Pat. Appl. 1572997.
; Chem. Abstr. 1970, 72, 90495
4b Kusuda F, Murayama M, and Takahashi H. inventors; Jap.
Pat. Appl. 7118996.
; Chem. Abstr. 1971, 75, 49128
4c Takahashi H. inventors; Jap.
Pat. Appl. 7118995.
; Chem. Abstr. 1971, 75, 63823
5a
Armarego WLF.
Advances in Heterocyclic Chemistry
Vol.
1:
Katritzky AR.
Academic
Press;
New York:
1963.
p.253
5b
Armarego WLF.
Advances in
Heterocyclic Chemistry
Vol. 24:
Katritzky AR.
Academic Press;
New
York:
1979.
p.1
5c
Brown DJ.
Comprehensive Heterocyclic
Chemistry
Vol. 3:
Katritzky AR.
Rees CW.
Pergamon;
Oxford:
1984.
p.57
5d
Undheim K.
Comprehensive Heterocyclic Chemistry II
Katritzky AR.
Rees CW.
Scriven EF.
Pergamon;
Oxford:
1996.
p.93
6
Weinstein L.
Chang TW.
Hudson JB.
Antibiot. Chemother.
1957,
7:
443
7
Perlman D.
Barrett JM.
Can. J. Microbiol.
1958,
4:
9
8
Ishikawa F.
Kosasayama A.
Higashi K.
Chem.
Pharm. Bull.
1980,
28:
2024
9a
Meguro K.
Tawada H.
Kuwada Y.
Chem. Pharm. Bull.
1973,
21:
1619
9b
Derieg ME.
Fryer RJ.
Hillery SS.
Metlesics W.
Silverman G.
J. Org. Chem.
1971,
36:
782
9c
Hirai K.
Fujishita T.
Ishiba T.
Sugimoto H.
Matsutani S.
Tsukinoki Y.
Hirose K.
J.
Med. Chem.
1982,
25:
1466
10
Bahr F.
Dietz G.
Pharmazie
1980,
35:
256
11
Hirai K.
Ishiba T.
Sugimoto H.
Fujishita T.
J. Org. Chem.
1981,
46:
4489
12
Hara T.
Kayama Y.
Sunami T.
J.
Org. Chem.
1978,
43:
4865
13a
Zimaity T.
Anwar M.
Abdel-Hay FI.
Abdel-Megeid FME.
Acta Chim. Acad. Sci. Hung.
1975,
87:
251
13b
Elkaschef MA.-F.
Abdel-Megeid FME.
Abdel-Kader A.
Collect. Czech. Chem. Commun.
1974,
39:
287
13c
Abdel-Megeid FME.
Elkaschef MA.-F.
Mokhtar K.-EM.
Zaki K.-EM.
J. Chem. Soc. C
1971,
1055
14
Yamagishi M.
Ozaki K.-I.
Yamada Y.
Da-te T.
Okamura K.
Suzuki M.
Chem. Pham. Bull.
1991,
39:
1694
15
Burlaka BM.
Khim.
Geterotsikl. Soedin.
1980,
708
16
Kim K.
Sulfur
Reports
1998,
21:
147
17
Lee H.-S.
Chang Y.-G.
Kim K.
J.
Heterocycl. Chem.
1998,
35:
659
18
Appel R.
Janssen H.
Siray M.
Knoch G.
Chem. Ber.
1985,
118:
1632
19
General Procedure
for the Synthesis of 3-Aryl-2-cyanoquinazolin-4(3
H
)-ones 2. (A)
To a solution of methyl N-(4-chloro-5H-1,2,3-dithiazol-5-ylidene)anthranilate
(1) (0.42-0.94 mmol) in CH2Cl2 (20
mL) was added TiCl4 (0.82-1.37 mmol) by using
a hypodermic syringe under nitrogen atmosphere. The solution turned
immediately dark red. Arylamines (1.86-3.78 mmol) were
added to the dark red solution, which was stirred until no spot
corresponding to 1 was observed on TLC
(silica gel, R
f = 0.6,
EtOAc-hexane = 1:3). Water (30 mL) was added and
the mixture was extracted with CH2Cl2 (25
mL × 3). The combined extracts were dried over MgSO4,
followed by evaporation of the solvent. The residue was chromatographed
on a silica gel (70-230 mesh, 2 × 10 cm). Elution
with n-hexane gave sulfur. Subsequent
elution with a mixture of n-hexane and EtOAc
(5:1) gave unknown mixtures and 2. (B)
To a solution of 2-[N-(4-chloro-5H-1,2,3-dithiazol-5-ylidene)]acetophenone
(5c) (0.36-0.59 mmol) in CH2Cl2 (15 mL)
was added TiCl4 (0.55-0.64 mmol) by using a hypodermic
syringe under nitrogen atmosphere. Subsequently arylamines were
added. When p-toluidine was added, the
reaction mixture showed a yellow spot (R
f = 0.7, EtOAc-n-hexane = 1:3), assignable
to be 3,4-dihydro-4-methylene-3-(4-tolyl)quinazoline-2-carbonitrile
(9a). IR (neat): 2240, 1635, 1603, 1581,
1555, 1504, 1469, 1344, 1322, 1226, 1206, 1110, 816, 762 cm-1. 1H
NMR (CDCl3, 300 MHz): δ = 2.47 (s,
3 H, CH3), 3.61 (d, 1 H, J = 2.5
Hz, =CH), 4.65 (d, 1 H, J = 2.5
Hz, =CH), 7.26-7.32 (m, 3 H, ArH), 7.36-7.52
(m, 4 H, ArH), 7.53 (d, 1 H, J = 7.8
Hz, ArH). 13C NMR (CDCl3,
75 MHz): δ = 21.8, 85.0, 112.1, 123.4, 123.7,
128.2, 128.9, 129.4, 131.1, 131.9, 133.1, 135.9, 140.8, 141.0, 142.8.
Anal. Calcd for C17H13N3: C, 78.74;
H, 5.05; N, 16.20. Found: C, 78.62; H, 5.09; N, 16.35. Compound 9a gradually faded out during chromatography to
give a new spot (R
f = 0.5,
EtOAc-n-hexane = 1:
3), corresponding to 2-cyano-3-(4-tolyl)quinazolin-4(3H)-one (2b),
which was eluted with a mixture of EtOAc and n-hexane
(1:5) as an eluent to give 2b, which was recrystallized
from EtOH. Mp 175-176 °C. IR (KBr): 1677, 1581, 1501, 1456,
1328, 1312, 1274, 1104, 1082, 810, 774 cm-1. 1H
NMR (CDCl3, 300 MHz): δ = 2.49 (s,
3 H, CH3), 7.31 (d, 2 H, J = 8.3
Hz, ArH), 7.43 (d, 2 H, J = 8.3
Hz, ArH), 7.67-7.73 (m, 1 H, ArH), 7.82-7.92 (m,
2 H, ArH), 8.38 (d, 1 H, J = 7.6
Hz, ArH). 13C NMR (CDCl3,
75 MHz): δ = 21.9, 111.6, 123.4, 127.9, 128.3,
129.1, 130.7, 131.2, 132.1, 132.9, 135.8, 141.5, 146.9, 160.6. Anal.
Calcd for C16H11N3O: C, 73.55;
H, 4.24; N, 16.08. Found: C, 73.50; H, 4.22; N, 16.21.
20
General Procedure
for the Synthesis of 3-Aryl-3,4-dihydro-4-hydroxy-4-phenylquinazoline-4-carbonitriles 6. To
a solution of 2-[N-(4-chloro-5H-1,2,3-dithiazol-5-ylidene)]benzophenone
(5a) (0.29-0.41 mmol) in CH2Cl2 (15
mL) was added TiCl4 (0.46-0.91 mmol) by using
a hypodermic syringe under nitrogen atmosphere, followed by addition
of arylamines (0.61-1.03 mmol). The mixture was worked
up as described in the general procedure for the synthesis of 2. Elution with a mixture of n-hexane and EtOAc (3:1) gave 6a,b and 6f. 4-Hydroxy-3-(4-methoxyphenyl)-4-phenylquinazoline-2-carbonitrile
(6a), which was recrystallized from a mixture
of CH2Cl2 and n-hexane.
Mp 179-182 °C (dec.). IR (KBr): 3168, 2224, 1597, 1578,
1454, 1467, 1446, 1354, 1290, 1248, 1168, 1030, 995, 819, 765, 733
cm-1. 1H NMR (CDCl3,
300 MHz): δ = 3.73 (s, 3 H, OCH3 of
major), 3.84 (s, 3 H, OCH3 of minor), 5.99 (s, br, 1
H, OH of major), 6.60-6.66 (m, 2 H, ArH of major), 6.80-6.82
(m, 1 H ArH of major), 6.89 (d, 1 H, J = 7.4
Hz, ArH of major), 7.12-7.26 (m, 6 H, ArH of major), 7.39-7.53 (m,
2 H, ArH of major), 7.74-7.76 (m, 1 H, ArH of major). 13C
NMR (CDCl3, 75 MHz): δ = 55.3, 87.6,
112.0, 113.7, 124.7, 127.6, 128.1, 128.1, 128.2, 128.3, 129.7, 129.8, 131.1,
133.1, 134.3, 139.0, 141.8, 159.7. The aromatic proton signals of
minor compound are envisaged to overlap with those of major. Anal.
Calcd for C22H17N3O2:
C, 74.35; H, 4.82; N, 11.82. Found: C, 74.49; H, 4.80; N, 11.71.
21
Okabayashi I.
Fujiwara H.
J. Heterocycl. Chem.
1984,
21:
1401